Neutrophil Gelatinase Associated Lipocalin in Acute Kidney Injury

Peacock, W. Frank; Maisel, Alan S.; Kim, Jieun; Ronco, Claudio

doi:10.3810/pgm.2013.11.2715

Cited by 24 publications

(9 citation statements)

References 197 publications

(261 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AKI can have an incidence of up to 7% in the emergency department. There is a limited applicability of the RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease) criteria in the emergency setting because of a lack of baseline sCr measures; therefore, the additive value of NGAL testing in AKI, and NGAL and brain natriuretic peptide (BNP) testing in cardiorenal syndrome, becomes remarkable in clinical judgment accuracy as well as in patient risk stratification [ 12 ].…”

Section: Early Diagnosis Of Acute Kidney Injurymentioning

confidence: 99%

Biomarkers for acute kidney injury: is NGAL ready for clinical use?

Ronco

2014

Crit Care

Self Cite

View full text Add to dashboard Cite

The RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease) criteria were introduced in 2004, defining the clinical stage of acute kidney injury (AKI) and outcome measures based on serum creatinine, glomerular filtration rate, and urine output. However, a growing body of evidence suggests that these markers are insufficient in drawing an accurate illustration of kidney injury. Indeed, mortality and morbidity remain high in AKI, suggesting that accuracy and speed of patient evaluation are lacking. A great deal of evidence indicates that neutrophil gelatinase-associated lipocalin (NGAL) is a sensitive and specific early marker of various etiological classes of AKI and would be highly valuable in conjunction with existing markers of AKI for better classifying renal injury as well as dysfunction (kidney attack). Improvements in diagnosis, risk identification, stratification, prognosis, and therapeutic monitoring will benefit clinical decision-making in the individualized bundling of therapies and ongoing patient management. In particular, kidney protection and AKI prevention may become feasible if an earlier and more accurate diagnosis is made for AKI. Here, we discuss the opportunity to consider whether NGAL is ready for routine clinical use in a number of etiologies of AKI.

show abstract

Section: Early Diagnosis Of Acute Kidney Injurymentioning

confidence: 99%

Biomarkers for acute kidney injury: is NGAL ready for clinical use?

Ronco

2014

Crit Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…В норме NGAL стимулирует дифференцировку и структурную реорганизацию ренальных эпителиальных клеток. При развитии ренальных заболеваний уровни NGAL в сыворотке крови возрастают и коррелируют с тяжестью патологии [13][14][15][16][17].…”

Section: Ngal -ранний маркер оппunclassified

“…-антиинфекционное бактериостатическое действие на дистальный урогенитальный тракт [13][14][15][16][17].…”

Section: Ngal -ранний маркер оппunclassified

“…Четко и многократно показано: при повреждении ренальных канальцев происходит повышение уровня s-NGAL в 7-15 раз, u-NGAL в 25-1000 раз! Комплексное измерение s-NGAL и u-NGAL дает весьма ценную, специфичную и, самое главное, своевременную прогностическую информацию о развитии ОПП [13][14][15][16][17].…”

Section: Ngal -ранний маркер оппunclassified

See 1 more Smart Citation

Cystatin C and NGAL - the Markers of Preclinical Renal Dysfuction and Subclinical Acute Kidney Injury

Velkov¹

2015

Lab. sluzh.

View full text Add to dashboard Cite

“…[ 4 ] Neutrophil gelatinase associated lipocalin (NGAL) is one of the most promising AKI biomarkers. [ 5 6 ] Some of the major biomarkers studied in this review are ST 2 , Galectin-3, and Adrenomedullin.…”

Section: Novel Biomarkersmentioning

confidence: 99%

Role of point of care - ST ₂ , Galectin-3 and adrenomedullin in the evaluation and treatment of emergency patients

Siler-Fisher

Tucci

Kalra³

et al. 2014

Int J Crit Illn Inj Sci

View full text Add to dashboard Cite

There have been many technological advances improving the work up and treatment of patients in the emergency department (ED). Point of care testing (POCT) is becoming more common, especially in the time compressed clinically high-pressured environment of the emergency department. In present times, emphasis of POCT has spurred search of novel biomarkers which promise earlier and more specific detection of disease. This article reviews the role of ST2, Galectin-3 and Adrenomedullin in the acute care setting addressing the screening, diagnostic, and prognostic role of each marker for stratification of patients. Use of these markers has shown a strong correlation with early identification and efficient management in the ED.

show abstract

Neutrophil Gelatinase Associated Lipocalin in Acute Kidney Injury

Cited by 24 publications

References 197 publications

Biomarkers for acute kidney injury: is NGAL ready for clinical use?

Biomarkers for acute kidney injury: is NGAL ready for clinical use?

Cystatin C and NGAL - the Markers of Preclinical Renal Dysfuction and Subclinical Acute Kidney Injury

Role of point of care - ST ₂ , Galectin-3 and adrenomedullin in the evaluation and treatment of emergency patients

Contact Info

Product

Resources

About

Neutrophil Gelatinase Associated Lipocalin in Acute Kidney Injury

Cited by 24 publications

References 197 publications

Biomarkers for acute kidney injury: is NGAL ready for clinical use?

Biomarkers for acute kidney injury: is NGAL ready for clinical use?

Cystatin C and NGAL - the Markers of Preclinical Renal Dysfuction and Subclinical Acute Kidney Injury

Role of point of care - ST 2 , Galectin-3 and adrenomedullin in the evaluation and treatment of emergency patients

Contact Info

Product

Resources

About

Role of point of care - ST ₂ , Galectin-3 and adrenomedullin in the evaluation and treatment of emergency patients